PL203161B1 - Pochodne oksadiazolu, kompozycja farmaceutyczna je zawierająca oraz zastosowanie pochodnej oksadiazolu do wytwarzania leku do leczenia raka - Google Patents
Pochodne oksadiazolu, kompozycja farmaceutyczna je zawierająca oraz zastosowanie pochodnej oksadiazolu do wytwarzania leku do leczenia rakaInfo
- Publication number
- PL203161B1 PL203161B1 PL359415A PL35941501A PL203161B1 PL 203161 B1 PL203161 B1 PL 203161B1 PL 359415 A PL359415 A PL 359415A PL 35941501 A PL35941501 A PL 35941501A PL 203161 B1 PL203161 B1 PL 203161B1
- Authority
- PL
- Poland
- Prior art keywords
- compound
- alkyl
- optionally substituted
- halogen
- dmso
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000120234 | 2000-04-21 | ||
PCT/JP2001/003214 WO2001083463A1 (fr) | 2000-04-21 | 2001-04-16 | Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaires |
Publications (2)
Publication Number | Publication Date |
---|---|
PL359415A1 PL359415A1 (en) | 2004-08-23 |
PL203161B1 true PL203161B1 (pl) | 2009-08-31 |
Family
ID=18631080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL359415A PL203161B1 (pl) | 2000-04-21 | 2001-04-16 | Pochodne oksadiazolu, kompozycja farmaceutyczna je zawierająca oraz zastosowanie pochodnej oksadiazolu do wytwarzania leku do leczenia raka |
Country Status (16)
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
WO2005012268A1 (ja) | 2003-07-30 | 2005-02-10 | Shionogi & Co., Ltd. | イソオキサゾール環を有するスルホンアミド誘導体 |
US7659294B2 (en) * | 2004-10-22 | 2010-02-09 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
US7576222B2 (en) | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
MX2008013990A (es) * | 2006-05-09 | 2009-01-29 | Pfizer Prod Inc | Derivados de cicloalquilamino acidos. |
KR100783585B1 (ko) | 2006-08-22 | 2007-12-07 | 한국생명공학연구원 | 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제 |
MX2010002258A (es) | 2007-08-27 | 2010-04-22 | Helicon Therapeutics Inc | Compuestos terapeuticos de isoxazol. |
RU2010128006A (ru) * | 2007-12-10 | 2012-01-20 | Актелион Фармасьютиклз Лтд (Ch) | Производные тиофена в качестве агонистов sipi/edgi |
AR077969A1 (es) | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
CN103450167A (zh) * | 2012-05-28 | 2013-12-18 | 南京大学 | 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途 |
US10710994B2 (en) * | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
AU2020373047A1 (en) | 2019-10-31 | 2022-05-19 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
CN113264899B (zh) * | 2021-04-09 | 2022-06-14 | 台州学院 | 一种1,3,5-噁二嗪类化合物及其制备和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9811521A (pt) * | 1997-07-22 | 2000-08-22 | Shionogi & Co | Composição para tratar ou impedir a glomerulopatia |
WO2000015213A1 (fr) | 1998-09-11 | 2000-03-23 | Shionogi & Co., Ltd. | Agent de prevention ou de traitement de l'insuffisance cardiaque congestive |
-
2001
- 2001-04-16 JP JP2001580892A patent/JP3974781B2/ja not_active Expired - Fee Related
- 2001-04-16 KR KR1020027013969A patent/KR100542780B1/ko not_active IP Right Cessation
- 2001-04-16 EP EP01919938A patent/EP1277744A4/en not_active Withdrawn
- 2001-04-16 HU HU0300619A patent/HUP0300619A3/hu unknown
- 2001-04-16 WO PCT/JP2001/003214 patent/WO2001083463A1/ja not_active Application Discontinuation
- 2001-04-16 US US10/257,917 patent/US6720343B2/en not_active Expired - Fee Related
- 2001-04-16 PL PL359415A patent/PL203161B1/pl not_active IP Right Cessation
- 2001-04-16 AU AU2001246916A patent/AU2001246916B2/en not_active Ceased
- 2001-04-16 CA CA002406685A patent/CA2406685C/en not_active Expired - Fee Related
- 2001-04-16 CN CNB018112404A patent/CN1199956C/zh not_active Expired - Fee Related
- 2001-04-16 RU RU2002130247/04A patent/RU2275371C2/ru not_active IP Right Cessation
- 2001-04-16 BR BR0110211-7A patent/BR0110211A/pt not_active Withdrawn
- 2001-04-16 MX MXPA02010325A patent/MXPA02010325A/es active IP Right Grant
- 2001-04-16 AU AU4691601A patent/AU4691601A/xx active Pending
- 2001-04-19 TW TW090109406A patent/TWI294877B/zh not_active IP Right Cessation
-
2002
- 2002-10-15 ZA ZA200208307A patent/ZA200208307B/xx unknown
- 2002-10-18 NO NO20025035A patent/NO324868B1/no not_active IP Right Cessation
-
2003
- 2003-12-10 US US10/730,946 patent/US20040122066A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2275371C2 (ru) | 2006-04-27 |
BR0110211A (pt) | 2003-06-03 |
ZA200208307B (en) | 2003-10-15 |
CN1436179A (zh) | 2003-08-13 |
JP3974781B2 (ja) | 2007-09-12 |
CN1199956C (zh) | 2005-05-04 |
MXPA02010325A (es) | 2003-04-25 |
US20030203940A1 (en) | 2003-10-30 |
NO20025035D0 (no) | 2002-10-18 |
TWI294877B (US07585860-20090908-C00150.png) | 2008-03-21 |
US20040122066A1 (en) | 2004-06-24 |
US6720343B2 (en) | 2004-04-13 |
CA2406685C (en) | 2006-10-31 |
AU4691601A (en) | 2001-11-12 |
KR20030019357A (ko) | 2003-03-06 |
NO324868B1 (no) | 2007-12-17 |
KR100542780B1 (ko) | 2006-01-11 |
HUP0300619A2 (hu) | 2003-07-28 |
CA2406685A1 (en) | 2002-10-17 |
PL359415A1 (en) | 2004-08-23 |
EP1277744A4 (en) | 2007-07-11 |
EP1277744A1 (en) | 2003-01-22 |
NO20025035L (no) | 2002-12-19 |
HUP0300619A3 (en) | 2006-02-28 |
WO2001083463A1 (fr) | 2001-11-08 |
AU2001246916B2 (en) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL203161B1 (pl) | Pochodne oksadiazolu, kompozycja farmaceutyczna je zawierająca oraz zastosowanie pochodnej oksadiazolu do wytwarzania leku do leczenia raka | |
RU2707870C2 (ru) | N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина | |
CA2701053C (en) | Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors | |
CA2592118C (en) | Urea derivatives as enzyme modulators | |
CN102119047B (zh) | 作为dgat1抑制剂的杂芳基衍生物 | |
JP6506742B2 (ja) | Wnt経路モジュレーターとしてのプリンジオン | |
US20090048301A1 (en) | Heterocyclic compounds and their use as anticancer agents | |
JP2009542640A (ja) | 新ピリジン類似体 | |
JP2011502148A (ja) | 疼痛の治療用としてのp2x3受容体アンタゴニスト | |
AU2007230911A1 (en) | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | |
CN101605777A (zh) | 作为醛固酮合酶抑制剂的咪唑类化合物 | |
WO1999019303A1 (fr) | Derives de pyrazole | |
AU2005286701A1 (en) | Compounds for inflammation and immune-related uses | |
AU2007208151A1 (en) | Vinyl-phenyl derivatives for inflammation and immune-related uses | |
JP2012521428A (ja) | 疼痛治療用のp2x3受容体アンタゴニスト | |
JP2009542642A (ja) | 新規ピリジン類似体 | |
CA2961412A1 (en) | Inhibiting the transient receptor potential a1 ion channel | |
JP2009542641A (ja) | 新規ピリジン類縁体 | |
CN102464658A (zh) | 噁唑烷酮衍生物及其制备方法和用途 | |
JP3602513B2 (ja) | アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 | |
JP2009542643A (ja) | 新規ピリジン類似体 | |
WO2011007722A1 (ja) | 3-置換-2-フランカルボン酸ヒドラジド誘導体およびその薬学的に許容される塩 | |
CA2512813A1 (en) | Use of substituted 2-phenylbenzimidazoles as phamaceutical compositions | |
CN101289444B (zh) | 一种嘧啶衍生物及其医药用途 | |
CN110831937A (zh) | 嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Decisions on the lapse of the protection rights |
Effective date: 20120416 |